Jesse Aleman-Ortiz
Pulmonary Disease · Ponce, PRNPI 1104077213
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,702 of the $9,852 with a category attached, or 88.3%. It is spread thinly across 29 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.
Across 268 payments — averaging $36.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Bayer$1K
- GSK$1K
- Boehringer Ingelheim$893
- Actelion Pharmaceuticals US, Inc.$470
- Sanofi$452
- plus $3K from 23 others
Across 1 payment — averaging $2012.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2K
What the payments were for
- Consulting fees$1,00010%
- Travel & lodging$160%
- Food & beverage$8,70288%
- Education$1341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 72 | $2,081 |
| Bayer | 4 | $1,333 |
| GSK | 38 | $1,299 |
| Boehringer Ingelheim | 25 | $893 |
| Actelion Pharmaceuticals US, Inc. | 4 | $470 |
| Sanofi | 11 | $452 |
| Mylan Specialty L.p. | 13 | $433 |
| Johnson & Johnson | 12 | $400 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $399 |
| ANI Pharmaceuticals, Inc. | 18 | $330 |
| Merck | 10 | $254 |
| Jazz Pharmaceuticals Inc. | 7 | $227 |
| E.r. Squibb & Sons, L.L.C. | 2 | $148 |
| United Therapeutics Corporation | 3 | $147 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $145 |
| PBG Puerto Rico LLC | 7 | $127 |
| Amgen | 5 | $112 |
| Mallinckrodt Enterprises LLC | 1 | $95 |
| Teva Pharmaceuticals USA, Inc. | 3 | $90 |
| Mylan LLC | 5 | $89 |
| Mallinckrodt Hospital Products Inc. | 1 | $66 |
| Harmony Biosciences LLC | 2 | $50 |
| Olympus Latin America, Inc. | 2 | $49 |
| Chiesi USA, Inc. | 3 | $45 |
| Viatris Specialty LLC | 2 | $41 |
| Sandoz | 2 | $31 |
| Pfizer Pharmaceuticals LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Insmed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,852 in reported general payments places this provider in the 85th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 139 | $1,909,434 |
| OpsumitMacitentan | 135 | $1,699,900 |
| OfevNintedanib Esylate | 61 | $780,441 |
| Breo ElliptaFluticasone/Vilanterol | 503 | $212,606 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 221 | $152,861 |
| NucalaMepolizumab | 30 | $110,495 |
| Fasenra PenBenralizumab | 17 | $94,840 |
| TezspireTezepelumab-Ekko | 15 | $66,868 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 127 | $62,547 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 831 | $35,091 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 64 | $30,294 |
| Spiriva RespimatTiotropium Bromide | 55 | $29,412 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 93 | $24,686 |
| SymbicortBudesonide/Formoterol Fumarate | 72 | $17,113 |
| Atrovent HfaIpratropium Bromide | 28 | $13,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $1,333 | $1,909,434139 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $470 | $1,699,900135 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $893 | $878,744256 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta | $1,299 | $513,546853 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $2,081 | $91,31898 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Ponce
- Domingo Chardon FelicianoPonce$45K
- George FahedPonce$16K
- Giovanni Veloz IrizarryPonce$11K
- Dev Boodoosingh CasianoPonce$10K
- Keren Mendez RamirezPonce$8K
- Hector Puig-RamirezPonce$8K
- Sandra Galarza-VargasPonce$7K
- Ilean Lamboy HernandezPonce$5K
- Eugenio Rivera RiosPonce$3K
- Manuel Morell CataquetPonce$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.